Heart failure & cardiomyopathiesSecondary analysis
Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity
- Secondary analysis of a randomised controlled trial
- double-blind
- placebo-controlled
Authors' conclusion
Tirzepatide produced a comprehensive, meaningful improvement in heart failure across multiple complementary domains; enhanced health status, quality of life, functional capacity, exercise tolerance, and well-being; and reduced symptoms and medication burden in patients with heart failure with preserved ejection fraction and obesity.
Study context
- Population
- Patients with NYHA class II–IV HF, EF ≥50% and BMI ≥30 kg/m²median 104 weeks
- Participants
- 731 patients
- Comparison
- Tirzepatide vs placebo
- Tirzepatiden = 364
- Placebon = 367reference
- Primary endpoint
- CV death or worsening HF; KCCQ Clinical Summary Score
Primary result
As reported in the abstract
Tirzepatide vs PlaceboDifference, points (95% CI)P value
KCCQ Clinical Summary Score at 52 weeks
6.9(3.3–10.6)
P < 0.001- range across all composites of death and worsening HF, time to first event
- HR 0.41-0.67
Further findings
| Outcome | difference (meters) (95% CI) | P value | |
|---|---|---|---|
| 6-minute walk distance · 52 weeks | 18.3 (9.9–26.7) | P < 0.001 | |
| −2002040Difference, meters (linear scale) |
| Outcome | difference (95% CI) | P value | |
|---|---|---|---|
| EQ-5D-5L health state index · 52 weeks | 0.06 (0.03–0.09) | P < 0.001 | |
| −0.0500.050.1Difference (linear scale) |
| Outcome | proportional OR (95% CI) | P value | |
|---|---|---|---|
| Patient Global Impression of Severity Overall Health score · shift to more favorable score | 1.99 (1.44–2.76) | P < 0.001 | |
| NYHA class · shift to more favorable class | 2.26 (1.54–3.31) | P < 0.001 | |
| 0.20.5125Proportional or (log scale) |
HF medication use
- Fewer HF medications required with tirzepatide
- P = 0.015
Hierarchical composite (all-cause death, worsening HF, 52-week changes in KCCQ-CSS and 6-minute walk distance)
- Win ratio, benefit on the hierarchical composite
- 1.63 [95% CI, 1.17-2.28]; P=0.004
Original publication
Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity. Circulation. Published 18 November 2024. doi:10.1161/circulationaha.124.072679
Summarised from the published abstract; every number is checked against it